Skip to main content

Hepatology

Featured Article

Research Highlights
06/11/2026
Jessica Garlewicz
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found...
06/11/2026
Gastroenterology
FDA Approval
06/01/2026
Rebecca Mashaw
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
The approval provides the first...
06/01/2026
Gastroenterology
RESEARCH INSIGHTS
05/15/2026
Jessica Garlewicz
Importantly, MASLD was linked to increased all-cause mortality in young adults, driven primarily by cardiovascular and metabolic causes.
Importantly, MASLD was linked to increased all-cause mortality in young adults, driven primarily by cardiovascular and metabolic causes.
Importantly, MASLD was linked to...
05/15/2026
Gastroenterology
Research Highlights
05/07/2026
Jessica Garlewicz
The incidence of hepatocellular carcinoma remained low and did not differ significantly between procedures; rates of liver transplantation were comparable across groups.
The incidence of hepatocellular carcinoma remained low and did not differ significantly between procedures; rates of liver transplantation were comparable across groups.
The incidence of hepatocellular...
05/07/2026
Gastroenterology
Research Summary
05/07/2026
Jessica Garlewicz
The authors reported that MASLD showed a “nearly threefold rise over the study period” and was “independently associated with significantly higher morbidity.”
The authors reported that MASLD showed a “nearly threefold rise over the study period” and was “independently associated with significantly higher morbidity.”
The authors reported that MASLD...
05/07/2026
Gastroenterology
Research Review
05/06/2026
Rebecca Mashaw
Authors of research presented at Digestive Disease Week concluded that their findings support the “long-term durability, safety, and consistent NIT response of resmetirom in clinical practice.”
Authors of research presented at Digestive Disease Week concluded that their findings support the “long-term durability, safety, and consistent NIT response of resmetirom in clinical practice.”
Authors of research presented at...
05/06/2026
Gastroenterology
Research Review
05/06/2026
Jessica Garlewicz
The tiered strategy resulted in fewer hepatology referrals (5%) compared with the VCTE-first approach (15%), reflecting more conservative resource use.
The tiered strategy resulted in fewer hepatology referrals (5%) compared with the VCTE-first approach (15%), reflecting more conservative resource use.
The tiered strategy resulted in...
05/06/2026
Gastroenterology
Research Highlights
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
FDA Alert
03/20/2026
Rebecca Mashaw
The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
The US Food and Drug...
03/20/2026
Gastroenterology
Research Highlights
03/18/2026
Jessica Garlewicz
Findings of a recent analysis suggest that serial FIB-4 monitoring may provide prognostic value beyond a single baseline measurement.
Findings of a recent analysis suggest that serial FIB-4 monitoring may provide prognostic value beyond a single baseline measurement.
Findings of a recent analysis...
03/18/2026
Gastroenterology
Identification of Fibrosis
02/17/2026
Jessica Garlewicz
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
A new machine learning–based...
02/17/2026
Gastroenterology

Videos

Blanca Lizaolo-Mayo
Video
11/15/2024
Blanca Lizaolo-Mayo, MD
Dr Lizaolo-Mayo discusses factors to consider when diagnosing and treating patients without obesity or overweight who may have metabolic-associated steatohepatitis (MASH).
Dr Lizaolo-Mayo discusses factors to consider when diagnosing and treating patients without obesity or overweight who may have metabolic-associated steatohepatitis (MASH).
Dr Lizaolo-Mayo discusses...
11/15/2024
Gastroenterology
Video
06/14/2024
Kayla Monks, MS, RD
Kayla Monks, MS, RD, discusses nutritional needs and challenges of patients with liver disease, including candidates for transplant, and how to work with patients to achieve the best possible outcomes.
Kayla Monks, MS, RD, discusses nutritional needs and challenges of patients with liver disease, including candidates for transplant, and how to work with patients to achieve the best possible outcomes.
Kayla Monks, MS, RD, discusses...
06/14/2024
Gastroenterology
Videos
12/01/2020
In this video, Lauren Yang, MD, from Beth Israel Deaconess Medical Center, discusses what learned at the recent American Association for the Study of Liver Diseases annual meeting about research into managing hepatitis B.
In this video, Lauren Yang, MD, from Beth Israel Deaconess Medical Center, discusses what learned at the recent American Association for the Study of Liver Diseases annual meeting about research into managing hepatitis B.
In this video, Lauren Yang, MD,...
12/01/2020
Gastroenterology
Robert Fontana
Expert Insights
06/01/2026
Robert Fontana, MD
Dr Fontana recaps his presentation at Digestive Disease Week 2026 on advances in diagnosis and treatment for patients with MASLD and MASH, and the importance of collaboration among specialties as the numbers of patients with these conditions...
Dr Fontana recaps his presentation at Digestive Disease Week 2026 on advances in diagnosis and treatment for patients with MASLD and MASH, and the importance of collaboration among specialties as the numbers of patients with these conditions...
Dr Fontana recaps his...
06/01/2026
Gastroenterology
Zobair Younossi
Expert Insights
05/11/2026
Zobair Younossi, MD
Dr Younossi reviews his approach to managing MASLD and MASH, from screening to treatment to monitoring, and how working with a multidisciplinary team provides for better outcomes.
Dr Younossi reviews his approach to managing MASLD and MASH, from screening to treatment to monitoring, and how working with a multidisciplinary team provides for better outcomes.
Dr Younossi reviews his approach...
05/11/2026
Gastroenterology
Brian Lacy
Expert Insights
05/06/2026
Brian E. Lacy, PhD, MD
Dr Lacy explains some of the key changes in criteria for disorders of gut-brain interaction, including irritable bowel syndrome and abdominal pain/discomfort, found in the recently published ROME V.
Dr Lacy explains some of the key changes in criteria for disorders of gut-brain interaction, including irritable bowel syndrome and abdominal pain/discomfort, found in the recently published ROME V.
Dr Lacy explains some of the key...
05/06/2026
Gastroenterology
Expert Roundtable
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the...
04/17/2026
Gastroenterology
Expert Roundtable
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on...
04/17/2026
Gastroenterology
Expert Roundtable
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on...
03/30/2026
Gastroenterology
Expert Roundtable
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable...
03/30/2026
Gastroenterology
Expert Insights
03/11/2026
Megan Riehl, PsyD; Kate Scarlata, RDN
GI psychologist Megan Riehl and registered dietician and nutritionist Kate Scarlata discuss how their specialty care can help patients with constipation-predominant irritable bowel syndrome and which patients are the best candidates for...
GI psychologist Megan Riehl and registered dietician and nutritionist Kate Scarlata discuss how their specialty care can help patients with constipation-predominant irritable bowel syndrome and which patients are the best candidates for...
GI psychologist Megan Riehl and...
03/11/2026
Gastroenterology
Gut-Brain Interaction
02/05/2026
Megan Riehl, PsyD; Brooks D. Cash, MD; Anthony Lembo, MD
The final expert roundtable session focuses on when patients with IBS-C should be referred to GI psychologists for brain-gut therapy such as gut-directed hypnosis.
The final expert roundtable session focuses on when patients with IBS-C should be referred to GI psychologists for brain-gut therapy such as gut-directed hypnosis.
The final expert roundtable...
02/05/2026
Gastroenterology
Medication
01/29/2026
Anthony Lembo, MD; Megan Riehl, PsyD; Brooks D. Cash, MD
Our expert panel continues as Drs Cash, Lembo, and Riehl delve into the existing medications available to treat IBS-C, from neuromodulators to secretagogues and the sodium/hydrogen exchanger (NHE3) inhibitor tenapanor.
Our expert panel continues as Drs Cash, Lembo, and Riehl delve into the existing medications available to treat IBS-C, from neuromodulators to secretagogues and the sodium/hydrogen exchanger (NHE3) inhibitor tenapanor.
Our expert panel continues as...
01/29/2026
Gastroenterology

News

Research Highlights
06/11/2026
Jessica Garlewicz
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found...
06/11/2026
Gastroenterology
Research Highlights
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
Research Review
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Research Highlights
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Research Highlights
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology
Research Highlights
10/01/2025
Stephanie Holland
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized,...
10/01/2025
Gastroenterology
Research Highlights
09/15/2025
Rebecca Mashaw
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight...
09/15/2025
Gastroenterology
Research Highlights
06/11/2026
Jessica Garlewicz
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found...
06/11/2026
Gastroenterology
Research Insights
06/09/2026
Rebecca Mashaw
New research highlights important similarities and differences between IBS-C and Parkinson’s disease–associated constipation
New research highlights important similarities and differences between IBS-C and Parkinson’s disease–associated constipation
New research highlights...
06/09/2026
Gastroenterology
Research Review
06/03/2026
Jessica Garlewicz
Investigators observed a lower cumulative incidence of CRC among individuals who underwent colonoscopy across both age groups studied.
Investigators observed a lower cumulative incidence of CRC among individuals who underwent colonoscopy across both age groups studied.
Investigators observed a lower...
06/03/2026
Gastroenterology
Research Insights
05/27/2026
Rebecca Mashaw
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing...
05/27/2026
Gastroenterology
Research Review
05/27/2026
Jessica Garlewicz
The findings provide reassurance regarding prognosis in patients presenting with multiple primary tumors.
The findings provide reassurance regarding prognosis in patients presenting with multiple primary tumors.
The findings provide reassurance...
05/27/2026
Gastroenterology
Research Review
05/06/2026
Jessica Garlewicz
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained...
05/06/2026
Gastroenterology
Research Highlights
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
News
02/11/2026
Jessica Garlewicz
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key...
02/11/2026
Gastroenterology
Research Review
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology